



Formerly ASIT Biotech

February 28<sup>th</sup>, 2022

## Regulated information

### Information on the total number of voting rights and shares (in compliance with the dispositions of the law of May 2<sup>nd</sup>, 2007)

Brussels, Belgium, February 28<sup>th</sup>, 2022, 17:45 CET – DMS Imaging (formerly ASIT Biotech) (DMSIM - BE0974289218) publishes today the information in compliance with article 15 of the Belgian law of May 2<sup>nd</sup>, 2007, regarding the publication of major shareholdings.

Information on February 28<sup>th</sup>, 2022:

- Total amount of social capital: 66 071 856.50 €
- Total number of securities giving a Unique Voting Right: 1 489 607 331
- Total number of outstanding common shares: 1 489 607 331
- Total number of voting rights: 1 489 607 331

\*\*\*

### About DMS Imaging

Specialized in high technology for medical diagnosis, **DMS Imaging** is now the French leader in development, design and manufacture of RF imaging systems dedicated to radiology, bone densitometry, 3D modeling and posturology.

DMS Imaging is quoted on the Paris Euronext Market (ISIN: BE0974289218 - memo: DMSIM).

More information on <https://www.asitbiotech.com/fr/>.

#### Contacts

##### **DMS Imaging**

Samuel SANCERNI

Delphine de COURSON

General director

Chief Financial Officer

+33 4 67 50 49 00

+33 4 67 50 49 00